TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

PALO ALTO, Calif.--(BUSINESS WIRE)--Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year.

“The inclusion on TIME100 Health’s list is more than a personal honor,” said AmirAli Talasaz, Guardant Health co-CEO. “It is a recognition of the incredible technology that our Guardant team has built with the Shield blood test for colorectal cancer and Shield’s ability to save lives around the world. The result of over 10 years of research and development, the Shield blood test has the promise to detect multiple cancers at an early stage as we work to further advance screening access to empower patients, doctors, and healthcare systems to act sooner, improve treatment decisions, and ultimately save lives from multiple different types of cancers.”

“Being named to TIME100’s Health list is another testament that the dream we had to conquer cancer with data when we founded Guardant Health is coming to fruition and changing lives,” said Helmy Eltoukhy, Guardant Health Chairman and co-CEO. “In addition to the advancements we are making in early detection, our blood tests can replace invasive biopsies and enable cancer patients to get on the right treatments much faster. Guardant is redefining precision oncology, using our technology platform to provide dramatically more insights from cancer data that will allow us to be one step ahead of the disease and lower the total cost of care by knowing more upfront.”

Encouraging data for Guardant’s highly anticipated multi-cancer detection blood test was recently presented at the American Association for Cancer Research (AACR) annual meeting, building on the momentum of the FDA-approved Shield blood test for detection of colorectal cancer.

The Shield blood test is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit www.ShieldCancerScreen.com.

The full 2025 TIME100 Health list will appear in the May 26, 2025 print issue of TIME and at time.com/time100health.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.